Key facts
- Notable investors include Colopl Next.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Sangmyung Innovation
- ·The full record, as it builds
Funding rounds
No funding rounds for Sangmyung Innovation are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sangmyung Innovation
Developer of specialized drug delivery technologies designed to develop and commercialize advanced formulations for ophthalmic and systemic therapies. The company offers ocular implants and microarray patch (MAP) platforms to deliver treatments for conditions such as retinal diseases, glaucoma, osteoporosis, and obesity, enabling pharmaceutical and biotechnology companies to develop and manufacture drug delivery systems with enhanced precision, efficacy, and patient compliance.
- Sector
- Healthcare
- HQ
- Yongin, South Korea
- Founded
- 2022
- Employees
- 16
- Website
- sminnovation.com/
- Ownership
- Privately Held (backing)
Sangmyung Innovation doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sangmyung Innovation shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sangmyung Innovation in its N-PORT filings yet. We sweep new filings monthly.